Kristen O'Dwyer1, Peter Maslak. 1. Memorial Sloan-Kettering Cancer Center, Leukemia Service, Department of Medicine, New York, 10021, USA.
Abstract
BACKGROUND: Although originally developed as a cytarabine analog more than 40 years ago, azacitidine has been the subject of renewed interest in the era of cancer epigenetics. OBJECTIVE: What is the history of the clinical development of azacitidine and how has it been applied successfully to the treatment of myelodysplastic syndromes (MDS)? METHODS: We review the evolution of the use of azacitidine for the therapy of human disease and review the major studies that have laid the groundwork for its current clinical indication. CONCLUSION: The use of azacitidine has changed the approach to the treatment of MDS and has resulted in improved outcomes for patients.
BACKGROUND: Although originally developed as a cytarabine analog more than 40 years ago, azacitidine has been the subject of renewed interest in the era of cancer epigenetics. OBJECTIVE: What is the history of the clinical development of azacitidine and how has it been applied successfully to the treatment of myelodysplastic syndromes (MDS)? METHODS: We review the evolution of the use of azacitidine for the therapy of human disease and review the major studies that have laid the groundwork for its current clinical indication. CONCLUSION: The use of azacitidine has changed the approach to the treatment of MDS and has resulted in improved outcomes for patients.
Authors: Fabiana Cacace; Rossella Iula; Danilo De Novellis; Valeria Caprioli; Maria Rosaria D'Amico; Giuseppina De Simone; Rosanna Cuccurullo; William G Wierda; Kris Michael Mahadeo; Giuseppe Menna; Francesco Paolo Tambaro Journal: Biomedicines Date: 2022-06-14
Authors: Weili Sun; Timothy Triche; Jemily Malvar; Paul Gaynon; Richard Sposto; Xiaojing Yang; Henrique Bittencourt; Andrew E Place; Yoav Messinger; Chris Fraser; Luciano Dalla-Pozza; Bodour Salhia; Peter Jones; Alan S Wayne; Lia Gore; Todd M Cooper; Gangning Liang Journal: Blood Date: 2018-01-16 Impact factor: 25.476
Authors: Yi-An Ko; Davoud Mohtat; Masako Suzuki; Ae Seo Deok Park; Maria Concepcion Izquierdo; Sang Youb Han; Hyun Mi Kang; Han Si; Thomas Hostetter; James M Pullman; Melissa Fazzari; Amit Verma; Deyou Zheng; John M Greally; Katalin Susztak Journal: Genome Biol Date: 2013 Impact factor: 13.583